Purple Biotech (Israel) Performance
| PPBT Stock | ILA 11.10 1.80 13.95% |
The company holds a Beta of -0.61, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Purple Biotech are expected to decrease at a much lower rate. During the bear market, Purple Biotech is likely to outperform the market. Purple Biotech right now holds a risk of 16.16%. Please check Purple Biotech sortino ratio, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Purple Biotech will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Purple Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Purple Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 10.9 M |
Purple |
Purple Biotech Relative Risk vs. Return Landscape
If you would invest 1,640 in Purple Biotech on September 5, 2024 and sell it today you would lose (530.00) from holding Purple Biotech or give up 32.32% of portfolio value over 90 days. Purple Biotech is generating 0.0831% of daily returns and assumes 16.1611% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Purple on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Purple Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Purple Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Purple Biotech, and traders can use it to determine the average amount a Purple Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0051
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | PPBT |
| Negative Returns |
Estimated Market Risk
| 16.16 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Purple Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Purple Biotech by adding Purple Biotech to a well-diversified portfolio.
Purple Biotech Fundamentals Growth
Purple Stock prices reflect investors' perceptions of the future prospects and financial health of Purple Biotech, and Purple Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Purple Stock performance.
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (5 M) | |||
| Shares Outstanding | 205.98 M | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 56.01 X | |||
| EBITDA | (21.43 M) | |||
| Cash And Equivalents | 48.39 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 804 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.26 X | |||
| Cash Flow From Operations | (16.73 M) | |||
| Earnings Per Share | (0.11) X | |||
| Total Asset | 54.62 M | |||
About Purple Biotech Performance
By analyzing Purple Biotech's fundamental ratios, stakeholders can gain valuable insights into Purple Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Purple Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Purple Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel. PURPLE BIOTECH operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 13 people.Things to note about Purple Biotech performance evaluation
Checking the ongoing alerts about Purple Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Purple Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Purple Biotech had very high historical volatility over the last 90 days | |
| Purple Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (21.67 M) with loss before overhead, payroll, taxes, and interest of (55 K). | |
| Purple Biotech has accumulated about 48.39 M in cash with (16.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
- Analyzing Purple Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Purple Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Purple Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Purple Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Purple Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Purple Biotech's stock. These opinions can provide insight into Purple Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |